The patient was transplanted following conditioning with 16 mg/kg of BU, 200 mg/kg of CY and 30 mg/kg of thymoglobulin (ATG Fresenius). The total number of cells transplanted was 3.7 Â 10 7 /kg; the number of CD34 þ cells was 6 Â 10 5 /kg. Graft-versus-host prophylaxis included CsA only, from day À1, adjusted to a blood level of 100-200 mg/ ml. The early post-transplant period was complicated with Streptococcus mitis sepsis (day þ 8), interstitial pneumonia and idiopathic pneumonia syndrome (day þ 20), CMV reactivation (day þ 52) and acute GVHD-I of the skin. Neutrophil and platelet recovery occurred at days þ 30 and þ 100, respectively. At day þ 50, she was still 55% BCR/ ABL positive in the BM by FISH analysis and studies revealed mixed chimerism. At day þ 70, full chimerism was noted by both cytogenetic and PCR testing. The unit of cord blood with A Rh-positive blood group had engrafted.
Between days þ 80 and þ 152, she was hospitalized three times due to CMV pneumonitis, otitis media and catheterrelated septic shock, all treated successfully. During these infections, secondary pancytopenia was observed. She had been transfused many times with A Rh-positive K-negative (not selected in Rh phenotype)-packed red cells and/or filtrated and irradiated platelets. From day þ 153 she developed progressive complex hemolysis, resistant to all treatment modalities.
On day þ 167, the direct antiglobulin test (IgG þ , anti-C3d þ ) was positive; autoantibodies were found in the eluate from her red cells, whereas in her serum, anti-E alloantibody was identified ( Table 2) . Two weeks later, warm autoantibodies were found in the serum. Two months later, an additional alloantibody, anti-S, was detected; her MNS phenotype was typed as ss. On day þ 243, the direct antiglobulin test was positive; IgA(2 þ ) IgM(2þ ) were detected in addition to warm autoantibodies and anti-E alloantibodies. Anti-S was also detected. In the last sample, anti-E alloantibody was not detected. Direct antiglobulin test was positive with anti-IgG, -IgA, -IgM, -C3d and -C3c. Initially, she was treated with methylprednisolone 2 mg/kg i.v. followed by several pulses of 5 mg/kg of this drug, with no response. The patient was also treated with IGIV 0.5 g/kg, four doses of rituximab, mycophenolate mofetil, four cycles of CY 750 mg/m 2 /day and plasmapheresis, which was performed seven times without improvement of hemolysis. She was splenectomized on day þ 285. She died due to massive hemolysis on day þ 290.
Autoimmune hemolytic anemia (AIHA) is a well-known, but relatively rare, complication following hematopoietic SCT, reported in approximately 6% of children and 3% of adults. [3] [4] [5] AIHA is usually diagnosed about 2 months or later after transplantation and is caused mainly by warmtype autoantibodies. The etiology of AIHA is complex. The first significant decrease in hemoglobin level was observed in our patient 4 months after transplantation. Warm IgG autoantibodies were found 2 months later, and they coexisted with anti-E alloantibodies. From then on she was transfused with E-negative, K-negative red cells, but 2 months later, she produced anti-S alloantibodies. Almost at the same time her autoimmunity had progressed and coldtype autoantibodies were detected accompanied with warm type. Other causes of anemia, such as pure red cell aplasia, microangiopathic hemolytic anemia/thrombotic thrombocytopenic purpura or immune pancytopenia, were excluded.
Several cases of autoimmunization developing following alloimmunization in multiple transfused patients are reported in the literature. [6] [7] [8] Young et al. 8 presented two cases of AIHA concurrently with or shortly after alloimmunization due to blood transfusions. Our patient was multi-transfused; she received in total 58 U of red cells before symptoms of hemolysis has occurred, and the development of her autoantibodies was preceded by anti-E alloantibodies.
No improvement was observed after any of the therapies, and the progression of hemolysis was very rapid. Recently, two cases of successful therapy with monoclonal antibodies in patients with immune hemolytic anemia following UCBT in children have been reported: Radhi et al. 9 described the positive effect of use of two courses of rituximab in a girl with AIHA, whereas Chao et al. 10 successfully used alemtuzumab in a boy with refractory alloimmune hemolytic anemia.
Alloimmunization was probably the sequela of transplantation of partially matched two cord blood units, with discrepancies between blood groups as well as multitransfusion of blood products. Her earlier pregnancy (her son's blood group was O Rh positive) might also have induced susceptibility to immunization. Autoimmunization could develop due to frequent viral and bacterial infections, GVHD, antibiotics and other drugs. It could also be the effect of blood product transfusions. Other unknown factors could have an impact on the development of this fatal combined allo-and autoimmune hemolytic anemia occurring after double cord blood transplantation in this imatinib-resistant woman with CML. Letter to the Editor
